Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Tandem Diabetes (TNDM) to $20 from $22 and keeps an Equal Weight rating on the shares. The firm notes the company delivered a strong Q1 beat and reaffirmed 2025 guidance, though management’s comments imply Q2 sales below prior consensus. U.S. lives covered through pharmacy saw a nice increase in Q1 to 30%, Wells adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care: Strong Q1 Performance Amid Cautious Outlook and Hold Rating
- Tandem Diabetes Care Reports Record Q1 Sales Growth
- Tandem Diabetes Care’s Strong Q1 Performance and Growth Drive Buy Rating
- Closing Bell Movers: Microsoft and Meta rally after earnings
- Tandem Diabetes reports Q1 adjusted EBITDA ($4.7M) vs. ($14.4M)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue